Stay updated on Anetumab Ravtansine Multi-indication Clinical Trial
Sign up to get notified when there's something new on the Anetumab Ravtansine Multi-indication Clinical Trial page.

Latest updates to the Anetumab Ravtansine Multi-indication Clinical Trial page
- Check3 days agoChange DetectedThe ClinicalTrials.gov site revision changed from v3.8.0 to v3.8.1, with no change to the clinical trial record.SummaryDifference0.0%

- Check10 days agoChange DetectedThe Phase 1b study record for anetumab ravtansine is displayed with its study details, eligibility criteria, outcome measures, participating locations, and data-sharing information. The record indicates the study is completed and no longer recruiting.SummaryDifference86%

- Check17 days agoChange DetectedThe footer’s site revision label changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check31 days agoChange DetectedA sitewide NIH banner about website changes was added, and the footer revision changed from v3.7.1 to v3.7.2; the page still displays a 403 error.SummaryDifference1%

- Check45 days agoChange DetectedThe footer revision identifier changes from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check59 days agoChange DetectedThe page now displays a 403 Forbidden error with a minimal header and a Home link, replacing the previous detailed study content. Access to the study details is blocked on this page.SummaryDifference18%

Stay in the know with updates to Anetumab Ravtansine Multi-indication Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Anetumab Ravtansine Multi-indication Clinical Trial page.